Overall Survival Benefits for Combining Targeted Therapy as Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Published Data

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Qi, Wei Xiang ^a   Wang, Qiong ^a   Jiang, Yan Ling ^b   Sun, Yuan Jue ^a   Tang, Li na ^a   He, Ai na ^a   Min, Da liu ^a   Lin, Feng ^a   Shen, Zan ^a   Yao, Yang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; ENTINOSTAT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; K RAS PROTEIN; PLACEBO; R 1507; SORAFENIB; SUNITINIB; TIVANTINIB; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; COCHRANE LIBRARY; CONFIDENCE INTERVAL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; EGFR GENE; EMBASE; FATIGUE; GENE; GENE MUTATION; HAZARD RATIO; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; KRAS GENE; LUNG NON SMALL CELL CANCER; MEDLINE; META ANALYSIS; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT RESPONSE; WILD TYPE;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84873637882     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055637     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, et al. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98.
3. Belani CP, Goss G, Blumenschein G Jr, (2012) Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). Cancer Treat Rev 38: 173-184.
4. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957.
5. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, et al. (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25: 1545-1552.
6. Lin H, Jiang J, Liang X, Zhou X, Huang R, (2010) Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: A systematic review and meta-analysis. Lung Cancer 70: 57-62.
7. Qi WX, Tang LN, He AN, Shen Z, Yao Y, (2011) The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials. Lung 189: 437-443.
8. Tiwari D, Brodie SA, Brandes JC, (2012) Targeted therapy of non-small-cell lung carcinoma. Ther Adv Respir Dis 6: 41-56.
9. Passaro A, Cortesi E, de Marinis F, (2011) Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors? Expert Rev Anticancer Ther 11: 1587-1597.
10. Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, et al. (2011) Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 29: 1059-1066.
11. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132.
12. Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, et al. (2012) Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 13: 300-308.
13. Qi WX, Tang LN, He AN, Shen Z, Lin F, et al. (2012) Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison. Curr Med Res Opin 28: 643-650.
14. Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, et al. (2003) Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res 9: 1566-1572.
15. Tortora G, Caputo R, Damiano V, Troiani T, Veneziani BM, et al. (2003) Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity. Clin Cancer Res 9: 866-871.
16. Mortenson MM, Schlieman MG, Virudachalam S, Bold RJ, (2004) Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother Pharmacol 54: 343-353.
17. Custodio A, Mendez M, Provencio M, (2012) Targeted therapies for advanced non-small-cell lung cancer: current status and future implications. Cancer Treat Rev 38: 36-53.
18. Pennell NA, Lynch TJ Jr, (2009) Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 14: 399-411.
19. Rubin BP, Duensing A, (2006) Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors. Lab Invest 86: 981-986.
20. van der Kuip H, Wohlbold L, Oetzel C, Schwab M, Aulitzky WE, (2005) Mechanisms of clinical resistance to small molecule tyrosine kinase inhibitors targeting oncogenic tyrosine kinases. Am J Pharmacogenomics 5: 101-112.
21. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, et al. (1998) Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352: 609-613.
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
23. Parmar MK, Torri V, Stewart L, (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834.
24. NCI, Cancer Therapy Evaluation Program. CTC v 2.0 and common terminology criteria for adverse events criteria V3.0 (CTCAE). Available: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed 5 August 2012.
25. Kuritz SJ, Landis JR, Koch GG, (1988) A general overview of Mantel-Haenszel methods: applications and recent developments. Annu Rev Public Health 9: 123-160.
26. Zintzaras E, Ioannidis JP, (2005) Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 28: 123-137.
27. Yusuf S, Peto R, Lewis J, Collins R, Sleight P, (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27: 335-371.
28. Begg CB, Mazumdar M, (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
29. Dupont WD, Plummer WD Jr, (1998) Power and sample size calculations for studies involving linear regression. Control Clin Trials 19: 589-601.
30. Lynch TJ, Fenton D, Hirsh V, Bodkin D, Middleman EL, et al. (2009) A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J Thorac Oncol 4: 1002-1009.
31. Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, et al. (2011) Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. The Lancet 377: 1846-1854.
32. Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, et al. (2011) Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 29: 3307-3315.
33. Spigel DR, Burris HA, 3rd, Greco FA, Shipley DL, Friedman EK, et al (2011) Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol 29: 2582-2589.
34. Scagliotti GV, Krzakowski M, Szczesna A, Strausz J, Makhson A, et al. (2012) Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Phase III Trial. J Clin Oncol 30: 2070-2078.
35. Witta SE, Jotte RM, Konduri K, Neubauer MA, Spira AI, et al. (2012) Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy. J Clin Oncol 30: 2248-2255.
36. Ramalingam SS, Spigel DR, Chen D, Steins MB, Engelman JA, et al. (2011) Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol 29: 4574-4580.
37. Bennouna J, Besse B, Leighl NB, Blais N, Traynor AM, et al. (2010) Everolimus plus erlotinib versus erlotinib alone in previously treated patients with advanced non-small-cell lung cancer (NSCLC). Annals of oncology supl 21.abstr 419p.
38. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.
39. Jiang H, (2009) Overview of gefitinib in non-small cell lung cancer: an Asian perspective. Jpn J Clin Oncol 39: 137-150.
40. Yang CH, (2008) EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future. Lung Cancer 60Suppl 2: S23-30.
41. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, et al. (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527-1537.
42. Uhm JE, Park BB, Ahn MJ, Lee J, Ahn JS, et al. (2009) Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group. J Thorac Oncol 4: 1136-1143.